Literature DB >> 1568792

In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini.

H Takaku1, M Takase, S Abe, H Hayashi, K Miyazaki.   

Abstract

Arginine deiminase (EC 3.5.3.6) was purified to homogeneity from the cell extract of Mycoplasma arginini by molecular-sieve, anion-exchange and arginine-affinity chromatographies. The purified enzyme was composed of 2 identical sub-units with a molecular weight of 45.000 and had a pI of 4.7. Its Vmax value and Km value for L-arginine were estimated to be 50 units/mg protein and 0.2 mM, respectively. It exerted maximal enzyme activity at pH 6.0-7.5 and at 50 degrees C. The arginine deiminase was stable at neutral pH. When injected i.v. into mice, the half-life of the arginine deiminase in blood was about 4 hr. In culture, the enzyme strongly inhibited the growth of 6 kinds of mouse tumor cell lines by depleting L-arginine in the culture media. When the in vivo growth-inhibitory activity of arginine deiminase was tested for the 6 tumor cell lines, i.p. administration of the purified enzyme effectively prolonged the survival time of the mice injected with all kinds of the tumor cell lines. Especially, the in vivo growth of a hepatoma cell line, MH134, was completely prevented by the daily administration at a dose of 0.2 mg/mouse for 14 days. These results raise the possibility of the use of the arginine deiminase derived from Mycoplasma arginini as a new anti-tumor drug.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1568792     DOI: 10.1002/ijc.2910510213

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  36 in total

Review 1.  Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma.

Authors:  N Savaraj; M You; C Wu; M Wangpaichitr; M T Kuo; L G Feun
Journal:  Curr Mol Med       Date:  2010-06       Impact factor: 2.222

2.  Argininosuccinate synthase: at the center of arginine metabolism.

Authors:  Ricci J Haines; Laura C Pendleton; Duane C Eichler
Journal:  Int J Biochem Mol Biol       Date:  2011

Review 3.  Pegylated arginine deiminase: a novel anticancer enzyme agent.

Authors:  Lynn Feun; Niramol Savaraj
Journal:  Expert Opin Investig Drugs       Date:  2006-07       Impact factor: 6.206

4.  Arginine deprivation and tumour cell death: arginase and its inhibition.

Authors:  Denys N Wheatley; Ruth Philip; Elaine Campbell
Journal:  Mol Cell Biochem       Date:  2003-02       Impact factor: 3.396

Review 5.  Arginine catabolism, liver extracts and cancer.

Authors:  Denys N Wheatley; Elaine Campbell
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

6.  Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.

Authors:  Randie H Kim; Jodi M Coates; Tawnya L Bowles; Gregory P McNerney; Julie Sutcliffe; Jae U Jung; Regina Gandour-Edwards; Frank Y S Chuang; Richard J Bold; Hsing-Jien Kung
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

Review 7.  Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.

Authors:  Neha Kumari; Saurabh Bansal
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-26       Impact factor: 3.333

8.  A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients.

Authors:  T-S Yang; S-N Lu; Y Chao; I-S Sheen; C-C Lin; T-E Wang; S-C Chen; J-H Wang; L-Y Liao; J A Thomson; J Wang-Peng; P-J Chen; L-T Chen
Journal:  Br J Cancer       Date:  2010-08-31       Impact factor: 7.640

Review 9.  Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.

Authors:  Macus Tien Kuo; Niramol Savaraj; Lynn G Feun
Journal:  Oncotarget       Date:  2010-08

Review 10.  Arginine deprivation as a targeted therapy for cancer.

Authors:  L Feun; M You; C J Wu; M T Kuo; M Wangpaichitr; S Spector; N Savaraj
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.